Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

Neurology

Volumn 64, Issue 9, 2005, Pages 1553-1562

  Gilman, S ^a   Koller, M ^b   Black, R S ^c   Jenkins, L ^c   Griffith, S G ^b   Fox, N C ^d   Eisner, L ^e   Kirby, L ^f   Boada Rovira, M ^g   Forette, F ^h   Orgogozo, J M ⁱ  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b ELAN PHARMACEUTICALS   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Baumel Eisner Neuromedical Institute   (United States)

^f Pivotal Research Centers   (United States)

^g Institut Catala de Neurociencies Aplicades   (Spain)

^h Paris Descartes University   (France)

ⁱ UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; IMMUNOGLOBULIN G; QS 21; SODIUM CHLORIDE; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); ANTIBODY; PEPTIDE FRAGMENT; PLACEBO; VACCINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ACTIVE IMMUNIZATION; BLOOD; BRAIN; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODIES; BRAIN; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; INJECTIONS, INTRAMUSCULAR; MAGNETIC RESONANCE IMAGING; MALE; MENINGOENCEPHALITIS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PLACEBOS; TREATMENT OUTCOME; VACCINES;

EID: 20944448555     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000159740.16984.3C     Document Type: Article

References (27)

1. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995;373:523-527.
2. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177. Letter.
3. Morgan D, Diamond DM, Gottschall PE, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-985. Letter.
4. Janus C, Pearson J, McLaurin J, et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982. Letter.
5. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-8855.
6. McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002;8:1263-1269.
7. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 2005;64:94-101.
8. Orgogozo J-M, Gilman S, Dartigues J-F, et al. Subacute raeningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003;61:46-54.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
10. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
11. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects [online]. Available at: http://www.wma.net/e/policy/b3.htm#paragraphe29. Accessed May 27, 2004.
12. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
13. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 Suppl 2:S22-S32.
14. Gauthier S, Gelinas I, Gauthier L. Functional disability in Alzheimer's disease. Int Psychogeriatr 1997;9 Suppl 1:163-165.
15. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
16. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937-945.
17. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease. Arch Neurol 2000;57:339-344.
18. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussá F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004;14:11-20.
19. Masliah E, Hansen L, Adame A, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer's disease. Neurology 2005;64:129-131.
20. Andreasen N, Gottfries J, Vanmechelen E, et al. Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;71:557-558.
21. Thai LJ, Grundman M, Berg J, et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 2003;61:1498-1502.
22. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819-2826.
23. Schneider LS. Assessing outcomes in Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15 Suppl 1:S8-S18.
24. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003;9:448-452.
25. Pride MW, Black RW, Hagen M, et al. Evaluation of the cellular immune response in AD patients after immunotherapy with AN1792(QS-21). Poster 201.14. Presented at the 33rd meeting of the Society for Neuroscience; New Orleans, LA; November 8-12, 2003. Abstract available online at http://sfn.scholarone.com.
26. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38:547-554.
27. Hock C, Konietzko U, Papassotiropoulos A, et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002;8:1270-1275.